EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives

Andrea Citarella iD, Alessandro Dimasi, Davide Moi iD, Daniele Passarella iD, Angela Scala iD, Anna Piperno iD, Nicola Micale iD

Biomolecules · 02.09.2023 · 13 (9) · 1339

DOI: 10.3390/biom13091339 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 02.09.2023. Verfasst von Andrea Citarella und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Drug Treatment, Coronavirus 3C Proteases, Antiviral Agents. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Messina, FFABR_PA_MICALE_NICOLA_ATENEO_2022.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target. Disruption of the catalytic activity of Mpro produces a detrimental effect on the course of the infection, making this target one of the most attractive for the treatment of COVID-19. The current success of the SARS-CoV-2 Mpro inhibitor Nirmatrelvir, the first oral drug for the treatment of severe forms of COVID-19, has further focused the attention of researchers on this important viral target, making the search for new Mpro inhibitors a thriving and exciting field for the development of antiviral drugs active against SARS-CoV-2 and related coronaviruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 Drug TreatmentCoronavirus 3C ProteasesAntiviral AgentsProtease InhibitorsHumansLeucineProlineLactamsNitriles

Stichwörter der Autor:innen

COVID-19PaxlovidSARS-CoV-2 Mprocoronavirusnirmatrelvirpeptidomimeticsprotease inhibitors

Substanzen

Coronavirus 3C ProteasesAntiviral AgentsProtease InhibitorsnirmatrelvirLeucineProlineLactamsNitriles

Autor:innen und Institutionen

  • Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy.
  • Department of Chemical and Geological Sciences, University of Cagliari, S.P. 8 CA, 09042 Cagliari, Italy.
  • Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres 31, 98166 Messina, Italy.

ORCID-Profile: Andrea Citarella, Davide Moi, Daniele Passarella, Angela Scala, Anna Piperno, Nicola Micale

Förderung

  • University of Messina
  • FFABR_PA_MICALE_NICOLA_ATENEO_2022

Zitieren

APA

Citarella, A., Dimasi, A., Moi, D., Passarella, D., Scala, A., Piperno, A., & Micale, N. (2023). Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives. Biomolecules, 13(9), 1339. https://doi.org/10.3390/biom13091339

Vancouver

Citarella A, Dimasi A, Moi D, Passarella D, Scala A, Piperno A, et al. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives. Biomolecules. 2023;13(9):1339. doi:10.3390/biom13091339

BibTeX
@article{Citarella2023,
  author = {Citarella, Andrea and Dimasi, Alessandro and Moi, Davide and Passarella, Daniele and Scala, Angela and Piperno, Anna and Micale, Nicola},
  title = {Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {9},
  pages = {1339},
  doi = {10.3390/biom13091339}
}
Kostenlos starten →